Year of Publication
2024
College
Public Health
Date Available
8-14-2024
Degree Name
Master of Public Health (M.P.H.)
Committee Member
Dr. Jayani Jayawardhana
Advisor
Dr. Julia Costich
Co-Director of Graduate Studies
Dr. Chris Delcher
Abstract
This policy analysis examines the evolving landscape of GLP-1 receptor agonists (GLP-1 RAs) and their implications for Medicare Part D coverage. Initially developed for managing type 2 diabetes, GLP-1 RAs have rapidly gained popularity due to their efficacy in treating obesity and reducing cardiovascular events, leading to broader therapeutic applications. However, access to these medications under Medicare Part D is limited by high costs and coverage restrictions, particularly when used for obesity without diabetes. This analysis evaluates current Medicare Part D policies, including specialty drug tier placement, formulary restrictions, and the potential impact of recent legislative initiatives such as the Inflation Reduction Act and the Treat and Reduce Obesity Act. Through a comprehensive review of clinical trials, policy briefs, and economic assessments, the study identifies significant barriers to patient access and proposes policy reforms to improve the affordability and availability of GLP-1 RAs for Medicare beneficiaries. The findings underscore the need for Medicare to adapt its coverage frameworks to align with the expanding role of GLP-1 RAs in chronic disease management, ensuring equitable access for millions of beneficiaries.
Recommended Citation
Hummer, Celine, "Patient Access to GLP-1 RA’s: A Medicare Part D Policy Analysis" (2024). Theses and Dissertations--Public Health (M.P.H. & Dr.P.H.). 447.
https://uknowledge.uky.edu/cph_etds/447
